Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2242 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Ginsenoside Rk1
CAS:<p>Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.</p>Fórmula:C42H70O12Pureza:98.46% - 99.13%Cor e Forma:SolidPeso molecular:767(S)-Ro 32-0432
CAS:<p>(S)-Ro 32-0432 is a potent, selective inhibitor of protein kinase C (PKC) and G protein-coupled receptor kinase 5 (GRK5), demonstrating ATP-competitive and oral activity. It presents IC50 values of 9.3 nM for PKCα, 28 nM for PKCβI, 30 nM for PKCβII, 36.5 nM for PKCγ, and 108.3 nM for PKCε, showcasing its effectiveness against multiple PKC isoforms. Additionally, (S)-Ro 32-0432 inhibits T-cell activation, indicating its potential application in the research of chronic inflammatory and autoimmune diseases [1] [2].</p>Fórmula:C28H29ClN4O2Cor e Forma:SolidPeso molecular:489.01HDAC6/HSP90-IN-1
CAS:<p>HDAC6/HSP90-IN-1 is a potent dual inhibitor of HDAC6 and HSP90 with IC50s 4.3 nM & 46.8 nM, respectively; curbs PD-L1 and tumor growth in H1975 mice.</p>Fórmula:C28H37N3O6Cor e Forma:SolidPeso molecular:511.61QC6352
CAS:<p>QC6352 is a selective and effective KDM4C inhibitor (IC50: 35 nM).</p>Fórmula:C24H25N3O2Pureza:98%Cor e Forma:SolidPeso molecular:387.47GNE-049
CAS:<p>GNE-049 is a highly selective CBP inhibitor (IC50=1.1 nM) that blocks prostate cancer cell proliferation.</p>Fórmula:C27H32F2N6O2Pureza:98.67%Cor e Forma:SolidPeso molecular:510.58JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Fórmula:C18H21N4Na2O6PPureza:98%Cor e Forma:SolidPeso molecular:466.341PIM1-IN-1
CAS:<p>PIM1-IN-1 inhibits PIM1/3 with IC50s: PIM1 (7 nM), PIM2 (5530 nM), PIM3 (70 nM); it has anti-cancer properties.</p>Fórmula:C25H30N8O2Pureza:98%Cor e Forma:SolidPeso molecular:474.56CM-579 trihydrochloride (1846570-40-8 free base)
<p>CM-579 trihydrochloride is a first-in-class reversible and dual inhibitor of G9a and DNMT (IC50s: 16 nM, 32 nM) with potent in vitro cellular activity in a wide</p>Fórmula:C29H43Cl3N4O3Pureza:98%Cor e Forma:SolidPeso molecular:602.04Vafidemstat
CAS:<p>Vafidemstat (ORY-2001) is a lysine-histone demethylase (LSD1)/MAO-B inhibitor for the study of neurological disorders.</p>Fórmula:C19H20N4O2Pureza:99.53%Cor e Forma:SolidPeso molecular:336.39CD235
CAS:<p>CD235 is a structurally similar analog of CD161. CD161 is an orally bioavailable inhibitor of BET bromodomain.</p>Fórmula:C26H20FN5O2Pureza:98%Cor e Forma:SolidPeso molecular:453.47GSK-3484862
CAS:<p>Gsk-3484862 is a non covalent inhibitor of DNA methyltransferase DNMT1 with anticancer activity.</p>Fórmula:C19H19N5OSPureza:99.87% - 99.963%Cor e Forma:SolidPeso molecular:365.45YM-08
CAS:<p>YM-08 (Compound 7a), a brain-penetrant SIRT2 inhibitor, exhibits an IC50 of 19.9 μM. Additionally, it acts as an inhibitor of Hsp70 [1].</p>Fórmula:C19H17N3OS2Pureza:98%Cor e Forma:SolidPeso molecular:367.49MAK683-CH2CH2COOH
CAS:<p>MAK683-CH2CH2COOH, an EED-targeting chemical, serves as a foundation for EED degrader-1 and PROTAC EED degrader-2 design.</p>Fórmula:C23H21FN6O3Pureza:98%Cor e Forma:SolidPeso molecular:448.45(1s,4s)-Menin-MLL inhibitor-23
<p>(1s,4s)-Menin-MLL Inhibitor-23, an enantiomer of Menin-MLL Inhibitor-23 (Example 99A), functions as an inhibitor of the menin-MLL interaction [1].</p>Fórmula:C36H53FN6O4Cor e Forma:SolidPeso molecular:652.84PHD2/HDACs-IN-1
CAS:<p>PHD2/HDACs-IN-1: strong PHD2/HDAC inhibitor (IC50: 1.15-26.60 μM), low-toxicity, protects kidneys from cisplatin-induced AKI.</p>Fórmula:C18H19N9O4Cor e Forma:SolidPeso molecular:425.4BRD-IN-3
CAS:<p>BRD-IN-3 is a highly potent PCAF bromodomain (BRD) inhibitor (IC50: 7 nM). It also exhibits activity against GCN5 and FALZ.</p>Fórmula:C21H25N5O3Pureza:98%Cor e Forma:SolidPeso molecular:395.45SMYD3-IN-1
CAS:<p>SMYD3-IN-1 is an irreversible and selective SMYD3 (SET and MYND domain containing 3) inhibitor(IC50 of 11.7 nM).</p>Fórmula:C28H31ClN4O3Pureza:98%Cor e Forma:SolidPeso molecular:507.02TCS HDAC6 20b
CAS:<p>TCS HDAC6 20b (HDAC6-IN-7) is an HDAC6 inhibitor that blocks the growth of breast cancer cells and can be used in cancer research.</p>Fórmula:C26H44N2O4SPureza:>99.99%Cor e Forma:SolidPeso molecular:480.7KDM4-IN-2
CAS:<p>KDM4-IN-2 is a potent and selective KDM4/KDM5 dual inhibitor with Kis of 4 and 7 nM for KDM4A and KDM5B, respectively.</p>Fórmula:C25H26N6OPureza:98%Cor e Forma:SolidPeso molecular:426.51MK-0626
CAS:<p>MK-0626 is an orally available dipeptidyl peptidase IV (DPP-4) inhibitor enhancing AMP, restoring the expression of GLP-1R. promoting neoangiogenesis.</p>Fórmula:C22H24F2N6O2Pureza:99.47% - >99.99%Cor e Forma:SolidPeso molecular:442.46Tankyrase-IN-5
CAS:<p>Tankyrase-IN-5 (Compound 30f), structurally related to MSC2504877, effectively inhibits tankyrase isoforms TNKS1 and TNKS2, with half-maximal inhibitory</p>Fórmula:C17H18N2O2Pureza:98%Cor e Forma:SolidPeso molecular:282.34PRMT5-IN-28
CAS:<p>PRMT5-IN-28 (compound 36) serves as an inhibitor of the protein arginine methyltransferase 5 (PRMT5) enzyme, which is implicated in various cellular processes</p>Fórmula:C18H19ClN4O5Pureza:98%Cor e Forma:SolidPeso molecular:406.82Brepocitinib
CAS:<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Fórmula:C18H21F2N7OPureza:99.82%Cor e Forma:SolidPeso molecular:389.4JAK-IN-5
CAS:<p>JAK-IN-5 is a JAK inhibitor.</p>Fórmula:C27H31FN6OPureza:98.1% - 99.37%Cor e Forma:SolidPeso molecular:474.57PHD-IN-2
CAS:<p>PHD-IN-2 (Compound 91), a potent PHD antagonist with an IC50 of less than 5 nM, effectively stimulates erythropoietin synthesis in HEP3B cells with an EC50 of</p>Fórmula:C26H27N7O4Pureza:98%Cor e Forma:SolidPeso molecular:501.54PRMT5-IN-29
CAS:<p>PRMT5-IN-29 is a potent, orally active inhibitor of PRMT5, exhibiting an IC50 value of 1.5 μM, showing promise for use in advanced cancer research [1].</p>Fórmula:C18H20Cl3N5O5Pureza:98%Cor e Forma:SolidPeso molecular:492.74PRMT5-IN-25
CAS:<p>PRMT5-IN-25 (compound 503) is a potent inhibitor of PRMT5, exhibiting an inhibition constant (K i) of 0.06 nM and demonstrating antiproliferative properties [1</p>Fórmula:C24H21F3N6OPureza:98%Cor e Forma:SolidPeso molecular:466.46PARP7-IN-15
CAS:<p>PARP7-IN-15 (Compound 18) is a potent PARP7 inhibitor exhibiting an IC50 of 0.56 nM and demonstrates antitumor activity [1].</p>Fórmula:C23H24F6N6O4Pureza:98%Cor e Forma:SolidPeso molecular:562.46KDM5-C70
CAS:<p>KDM5-C70 is an ethyl ester derivative of KDM5-C49.</p>Fórmula:C17H28N4O3Pureza:97.63% - 99.86%Cor e Forma:SolidPeso molecular:336.43Pim-1 kinase inhibitor 5
CAS:<p>Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-</p>Fórmula:C22H13Cl2N3OPureza:98%Cor e Forma:SolidPeso molecular:406.26Sirtuin-1 inhibitor 1
CAS:<p>Sirtuin-1 inhibitor 1 is an inhibitor against deacetylase-1 (Sirtuin-1) and can be used to study senescence and cell death in the organism.</p>Fórmula:C20H17N3O2Pureza:99.1%Cor e Forma:SolidPeso molecular:331.37BRD7-IN-1
CAS:<p>BRD7-IN-1, a BI7273 derivative, forms PROTAC VZ185, targeting BRD7/9 with DC50s of 4.5/1.8 nM via VHL ligand linkage.</p>Fórmula:C22H28Cl2N4O3Pureza:98.95%Cor e Forma:SolidPeso molecular:467.39Aurora Kinases-IN-4
CAS:<p>Aurora Kinases-IN-4 (Compound 11c) is a covalent, ATP-competitive inhibitor of aurora kinase A with an IC50 value of 1.7 nM.</p>Fórmula:C26H28N8OPureza:98%Cor e Forma:SolidPeso molecular:468.55Physachenolide C
CAS:<p>Physachenolide C, a selective BET inhibitor, induces apoptosis and arrests the cell cycle at the G0-G1 phase, exhibiting antitumor activity [1].</p>Fórmula:C30H40O9Pureza:98%Cor e Forma:SolidPeso molecular:544.63PHD2-IN-1
CAS:<p>PHD2-IN-1, a potent and orally active HIF prolyl hydroxylase 2 (PHD2) inhibitor, exhibits an IC50 of 22.53 nM and is applicable in anemia research [1].</p>Fórmula:C21H23ClN4O5Pureza:98%Cor e Forma:SolidPeso molecular:446.88BET-IN-16
CAS:<p>BET-IN-16 (Comp I), a bromodomain and extra-terminal (BET) inhibitor, demonstrates anticancer activity by impeding the growth of prostate cancer cells.</p>Fórmula:C31H25N5O3Pureza:98%Cor e Forma:SolidPeso molecular:515.56Antitumor agent-101
CAS:<p>Antitumor agent-101 is a selective, covalent inhibitor targeting lysine methyltransferases G9a/GLP, demonstrating IC50 values of 8.5 nM for G9a and 5.5 nM for</p>Fórmula:C26H38N6O3Pureza:98%Cor e Forma:SolidPeso molecular:482.62SJ1461
CAS:<p>SJ1461 is a potent, orally active inhibitor of the BET family, selectively targeting and inhibiting BRD2 (BD1), BRD2 (BD2), BRD4 (BD1), and BRD4 (BD2) with</p>Fórmula:C21H18ClN7OS2Pureza:98%Cor e Forma:SolidPeso molecular:484CBP-IN-1
CAS:<p>CBP-IN-1 (compound 12) acts as a potent CBP inhibitor exhibiting an IC50 of 1.5 nM and additionally suppresses CBP BRET and BRD4(1) with IC50 values of 690 nM</p>Fórmula:C27H33F2N7OPureza:98%Cor e Forma:SolidPeso molecular:509.59Eleven-Nineteen-Leukemia Protein IN-2
CAS:<p>Eleven-Nineteen-Leukemia Protein IN-2 (compound 23), an ENL inhibitor, exhibits an IC50 of 10.7 nM and is utilized for leukemia research [1].</p>Fórmula:C22H23N5O2Pureza:98%Cor e Forma:SolidPeso molecular:389.45LSD1-UM-109
CAS:<p>LSD1-UM-109 is a highly potent and reversible inhibitor of LSD1, demonstrating an IC50 of 3.1 nM.</p>Fórmula:C29H27FN6Pureza:98%Cor e Forma:SolidPeso molecular:478.56Bromodomain inhibitor-12
CAS:<p>Bromodomain Inhibitor-12 (example 303) is a research compound utilized in the study of autoimmune and inflammatory diseases [1].</p>Fórmula:C28H38N4O5Pureza:98%Cor e Forma:SolidPeso molecular:510.63MAT2A-IN-10
CAS:<p>MAT2A-IN-10 (Compound 28), an orally active inhibitor of MAT2A, exhibits an IC50 of 26 nM and is utilized in cancer research [1].</p>Fórmula:C27H24F2N6O4Pureza:98%Cor e Forma:SolidPeso molecular:534.51PIM1-IN-4
CAS:<p>PIM1-IN-4: strong PIM1 inhibitor, also blocks SGK-1, PKA, CaMK-1, GSK3β, MSK1; promising for cancer studies.</p>Fórmula:C27H25BrCl2CuN6OPureza:98%Cor e Forma:SolidPeso molecular:663.88Eleven-Nineteen-Leukemia Protein IN-3
CAS:<p>ENL YEATS inhibitor Eleven-Nineteen-Leukemia Protein IN-3, IC50 15.4 nM, orally active, suppresses MYC, stabilizes ENL in vitro.</p>Fórmula:C28H27N5O2Pureza:98%Cor e Forma:SolidPeso molecular:465.55MAT2A-IN-12
CAS:<p>MAT2A Allosteric Inhibitor 2 is a potent, selective inhibitor exhibiting an IC50 of 5 nM and demonstrates nanomolar efficacy (IC50 = 5 μM) in proliferation</p>Fórmula:C20H17NO3Pureza:98%Cor e Forma:SolidPeso molecular:319.35CBP/p300-IN-21
CAS:<p>CBP/p300-IN-21 (Compound 5d), a selective inhibitor of CBP/p300 with IC50 values of 0.07 μM for p300 and 1.755 μM for CBP, reduces H3K18Ac levels and inhibits</p>Fórmula:C19H16ClNO4Pureza:98%Cor e Forma:SolidPeso molecular:357.79BRD4 Inhibitor-28
CAS:<p>BRD4 Inhibitor-28 (Compound 18), an orally active molecule, selectively inhibits the bromodomains of BRD4 (BRD4-BD1 and BRD4-BD2) with IC50 values of 15 and 55</p>Fórmula:C23H21N3O3Pureza:98%Cor e Forma:SolidPeso molecular:387.43Bromodomain inhibitor-12 (edisylate)
CAS:<p>Bromodomain Inhibitor-12 Edisylate (example 303) serves as a bromodomain inhibitor applicable to autoimmune and inflammatory disease research [1].</p>Fórmula:C30H44N4O11S2Pureza:98%Cor e Forma:SolidPeso molecular:700.82KH-3
CAS:<p>KH-3: HuR inhibitor, IC50 0.35 μM, halts cell growth, blocks HuR-FOXQ1 mRNA, curbs breast cancer invasion, slows lung colony growth.</p>Fórmula:C21H22N2O4S2Cor e Forma:SolidPeso molecular:430.54(S,R)-CFT8634
CAS:<p>(S,R)-CFT8634 is a selective and orally active BRD9 protein degrader with potential for researching BRD9-mediated disorders, such as abnormal cellular</p>Fórmula:C37H45F3N6O5Pureza:98%Cor e Forma:SolidPeso molecular:710.79FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Fórmula:C25H26N6O2Pureza:98%Cor e Forma:SolidPeso molecular:442.523WM-586
CAS:<p>WM-586 is a covalent inhibitor of WDR5 that impedes the WDR5-MYC binding.</p>Fórmula:C20H20F3N5O3SPureza:98%Cor e Forma:SolidPeso molecular:467.47JG-2016
CAS:<p>JG-2016, as a histone acetyltransferase 1 inhibitor, inhibits growth of human cancer cell lines and inhibits enzymatic activity in cellulose.</p>Fórmula:C18H21ClN4O3Pureza:99.00% - 99.37%Cor e Forma:SolidPeso molecular:376.84GSK217
CAS:<p>GSK217 is a potent and selective inhibitor of the bromo and extraterminal domain (BET) second bromodomain (BD2) with high solubility, utilized in oncology and</p>Fórmula:C20H20N6OPureza:98%Cor e Forma:SolidPeso molecular:360.41AGI-25696
CAS:<p>AGI-25696 inhibits MATA2, blocking MTAP-deleted tumor growth, potential for cancer research.</p>Fórmula:C27H18N4OPureza:98.40% - 99.74%Cor e Forma:SolidPeso molecular:414.46JAK-IN-31
CAS:<p>JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,</p>Fórmula:C21H19N7O2S2Pureza:98%Cor e Forma:SolidPeso molecular:465.55ABBV-712
CAS:<p>ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases</p>Fórmula:C24H28N4O5Pureza:98%Cor e Forma:SolidPeso molecular:452.5GSK737
CAS:<p>GSK737 is a dual inhibitor of BRD4 BD1 and BD2, exhibiting pIC50 values of 5.3 and 7.3, respectively.</p>Fórmula:C20H21N5O2Pureza:98%Cor e Forma:SolidPeso molecular:363.41AAPK-25
CAS:<p>AAPK-25, a dual Aurora/PLK inhibitor, disrupts mitosis, induces apoptosis, and has antitumor properties.</p>Fórmula:C21H13Cl2N3O2SPureza:97.05%Cor e Forma:SolidPeso molecular:442.32Demethyleneberberine chloride
CAS:<p>Demethyleneberberine chloride, a natural mitochondria-targeted antioxidant, mitigates colitis in mice and suppresses inflammatory responses by blocking the NF-</p>Fórmula:C19H18ClNO4Pureza:98%Cor e Forma:SolidPeso molecular:359.8Amelparib
CAS:<p>Amelparib (JPI-289) is an inhibitor of the poly-ADP-ribose polymerase.</p>Fórmula:C19H25N3O3Pureza:98%Cor e Forma:SolidPeso molecular:343.42BATCP
CAS:<p>BATCP is an inhibitor of histone deacetylases (HDAC) [1].</p>Fórmula:C23H28F3N3O6Cor e Forma:SolidPeso molecular:499.487AKB-6899
CAS:<p>AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated</p>Fórmula:C14H11FN2O4Pureza:97.87%Cor e Forma:SolidPeso molecular:290.25Sirt2-IN-5
CAS:<p>Sirt2-IN-5 is a potent inhibitor of SIRT2.</p>Fórmula:C26H27Cl2N5O3Cor e Forma:SolidPeso molecular:528.43MARK-IN-1
CAS:<p>MARK-IN-1 is a potent microtubule affinity regulating kinase (MARK) inhibitor, (IC50<0.25 nM).</p>Fórmula:C22H23F2N7OSPureza:98%Cor e Forma:SolidPeso molecular:471.53XDM-CBP
CAS:<p>XDM-CBP is an effective and selective CBP/p300 bromodomain inhibitor.</p>Fórmula:C21H22N2O4Pureza:98%Cor e Forma:SolidPeso molecular:366.41DY-46-2
CAS:<p>DY-46-2 is a DNMT3A inhibitor (IC50: 0.39 ± 0.23 μM) with anticancer activity and is used in cancer and tumor research.</p>Fórmula:C19H22N6O5SPureza:99.12% - 99.12%Cor e Forma:SolidPeso molecular:446.48Prolyl Hydroxylase inhibitor 1
CAS:<p>Prolyl Hydroxylase inhibitor 1 is an orally active inhibitor of hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) (IC50 of 62.23 nM).</p>Fórmula:C19H18ClN5O4Pureza:98%Cor e Forma:SolidPeso molecular:415.83K-756
CAS:<p>K-756 is a direct and selective inhibitor of tankyrase (TNKS), which inhibits the ADP-ribosylation activity of TNKS1 (IC50 = 31 nM) and TNKS2 (IC50 = 36 nM).</p>Fórmula:C24H27N5O3Pureza:99.81%Cor e Forma:SolidPeso molecular:433.5QL-1200186
CAS:<p>QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following</p>Fórmula:C26H27N7O3Pureza:98%Cor e Forma:SolidPeso molecular:485.54JAK kinase-IN-1
CAS:<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Fórmula:C17H19F2N7OSPureza:98%Cor e Forma:SolidPeso molecular:407.44JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Fórmula:C33H38F2N6O8Cor e Forma:SolidPeso molecular:684.69BChE/HDAC6-IN-1
CAS:<p>BChE/HDAC6-IN-1 is a dual BChE/HDAC6 inhibitor that exhibits potent and selective inhibition with IC50 values of 4 nM for BChE and 8.9 nM for HDAC6.</p>Fórmula:C34H43N5O5Pureza:98%Cor e Forma:SolidPeso molecular:601.74HDAC/HSP90-IN-3
CAS:<p>HDAC/HSP90-IN-3, a dual inhibitor targeting fungal Hsp90 (IC50: 0.83 μM) & HDAC (IC50: 0.91 μM), counters azole-resistant C. albicans.</p>Fórmula:C26H33N5O6Cor e Forma:SolidPeso molecular:511.57RK-701
CAS:<p>RK-701: G9a inhibitor, IC50 23-27 nM, increases HbF/γ-Globin/BGLT3, decreases H3K9me2, inhibits BCL11A/ZBTB7A.</p>Fórmula:C26H30N4O3Cor e Forma:SolidPeso molecular:446.54Aurora kinase inhibitor-8
CAS:<p>Aurora kinase inhibitor-8 is a highly selective inhibitor of Aurora kinase.</p>Fórmula:C30H29N7O3Cor e Forma:SolidPeso molecular:535.6EPZ-030456
CAS:<p>EPZ-030456 is an effective and selective inhibitor of the SMYD3.</p>Fórmula:C28H34ClN5O4SCor e Forma:SolidPeso molecular:572.12PF-06679142
CAS:<p>PF-06679142 is an effective AMPK activator. PF-06679142 exhibited robust activation of AMPK in rat kidneys as well as desirable oral absorption.</p>Fórmula:C20H17F2NO3Pureza:98%Cor e Forma:SolidPeso molecular:357.35CC-90005
CAS:<p>CC-90005 is a potent, selective oral PKC-θ inhibitor with an IC50 of 8 nM, preferential over PKC-δ, and inhibits T cell activation.</p>Fórmula:C21H27F2N7O2Cor e Forma:SolidPeso molecular:447.48GSK-A
CAS:<p>GSK-A is a Histone Lysine Methyltransferase EZH2 inhibitor.</p>Fórmula:C21H25N5O2Cor e Forma:SolidPeso molecular:379.46JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Fórmula:C19H17N5O4Pureza:98%Cor e Forma:SolidPeso molecular:379.37KDM2B-IN-1
CAS:<p>KDM2B-IN-1: Potent, specific KDM2B histone demethylase inhibitor for hyperproliferative disease research.</p>Fórmula:C21H30N4O2SCor e Forma:SolidPeso molecular:402.56PRMT5-IN-16
CAS:<p>PRMT5-IN-16 (Compound 20) is an antitumor PRMT5 inhibitor linked to epigenetic changes.</p>Fórmula:C25H34N8O2Cor e Forma:SolidPeso molecular:478.59OM-1700
CAS:<p>OM-1700 inhibits tankyrase 1 (IC50=127 nM) and 2 (IC50=14 nM); hinders colon cancer cell growth, COLO 320DM (GI50=650 nM).</p>Fórmula:C25H23FN6O2Cor e Forma:SolidPeso molecular:458.49Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Fórmula:C20H17N9Pureza:98%Cor e Forma:SolidPeso molecular:383.41FD1024
CAS:<p>FD1024 is a potent PIM inhibitor, displaying inhibitory concentrations (IC50s) of 1.96 nM, 38.9 nM, and 4.17 nM for PIM1, PIM2, and PIM3, respectively.</p>Fórmula:C21H20F2N4O2SPureza:98%Cor e Forma:SolidPeso molecular:430.47NMS-P515
CAS:<p>NMS-P515 is an effective, orally active, and stereospecific PARP-1 inhibitor (Kd: 16 nM and an IC50: 27 nM (in Hela cells)). It has anti-tumor activity.</p>Fórmula:C21H29N3O2Pureza:98%Cor e Forma:SolidPeso molecular:355.47CARM1-IN-3
CAS:<p>CARM1-IN-3 (compound 17b) is a potent, selective inhibitor of co-activator associated arginine methyltransferase (CARM1), exhibiting IC50 values of 0.07 µM for</p>Fórmula:C24H32N4O2Pureza:98%Cor e Forma:SolidPeso molecular:408.54RK-0133114
<p>RK-0133114, R-enantiomer of RK-701, is a G9a inhibitor (IC50 = 3.7 μM) for SCD research.</p>Fórmula:C26H30N4O3Cor e Forma:SolidPeso molecular:446.54JQKD82 dihydrochloride
CAS:<p>JQKD82 (JADA82) dihydrochloride, a cell-permeable and selective inhibitor of KDM5, enhances H3K4me3 levels, making it effective for multiple myeloma research [1].</p>Fórmula:C27H42Cl2N4O5Cor e Forma:SolidPeso molecular:573.55QQN-00358
CAS:<p>QQN-00358 is a novel potent and selective tankyrase (TNKS) inhibitor.</p>Fórmula:C26H24F3N3O4Cor e Forma:SolidPeso molecular:499.48MS31
CAS:<p>MS31 is a potent and highly affinity inhibitor of spindlin 1 (SPIN1).</p>Fórmula:C20H27N3O2Pureza:98%Cor e Forma:SolidPeso molecular:341.45Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Fórmula:C21H33F3N6O11Pureza:98%Cor e Forma:SolidPeso molecular:602.521CBP/p300-IN-15
CAS:<p>CBP/p300-IN-15 inhibits p300 (IC50: 2.5 nM) & CBP (28 nM), affects OVCAR-3 (EC50: 0.865 μM) & A2780 cells (2.71 μM) for ovarian cancer research.</p>Fórmula:C26H28N4O5Cor e Forma:SolidPeso molecular:476.52PARP1-IN-7
CAS:<p>PARP1-IN-7 functions as an anticancer agent by inhibiting poly(ADP-ribose) polymerase-1 (PARP1).</p>Fórmula:C24H23N5OCor e Forma:SolidPeso molecular:397.47Ro 32-0432 hydrochloride
CAS:<p>Ro 32-0432 is a selective, ATP-competitive, oral pan-PKC inhibitor exhibiting inhibitory effects on PKCα, PKCβI, PKCβII, PKCγ, and PKCε.</p>Fórmula:C28H28N4O2Pureza:98%Cor e Forma:SolidPeso molecular:452.55BET-IN-9
CAS:<p>BET-IN-9 is a BET inhibitor[1].</p>Fórmula:C22H24N4O3Cor e Forma:SolidPeso molecular:392.45PIN1 inhibitor 2
CAS:<p>PIN1 inhibitor 2, compound 12, impedes PIN1, shows promise in breast cancer study, and has IC50 of 9.55 μM in MCF7 cells.</p>Fórmula:C16H21N3S2Cor e Forma:SolidPeso molecular:319.49CBB1007
CAS:<p>CBB1007 is a potent, reversible, and substrate competitive LSD1 inhibitor (IC50: 5.27 μM for hLSD1).</p>Fórmula:C27H34N8O4Pureza:98%Cor e Forma:SolidPeso molecular:534.61
